Recombinant human interferon-gamma modulates Rift Valley fever virus infection in the rhesus monkey

J Interferon Res. 1991 Oct;11(5):297-304. doi: 10.1089/jir.1991.11.297.


Prophylactic treatment of rhesus macaques with 10(4)-10(6) U/kg of recombinant human interferon-gamma (rHuIFN-gamma) modulated Rift Valley fever (RVF) virus infection. IFN was given intramuscularly at 24 h prior to infection and daily thereafter for a total of five doses. After infection, treated monkeys showed no evidence of clinical disease; some had no detectable viremia; when viremia was observed, peak virus titers were decreased compared to control infected monkeys; and only minor and transient perturbations in hematologic and clinical chemistry values were seen. Untreated infected control monkeys developed high-titered viremia, mild to severe clinical disease, and moderate to severe changes in hemostatic parameters and clinical laboratory measurements. No evidence of synergism was noted when RVF virus-infected monkeys were treated prophylactically with combined low doses of rHuIFN-gamma and rHuIFN-alpha A.

MeSH terms

  • Animals
  • Disease Models, Animal
  • Drug Therapy, Combination
  • Hematologic Tests
  • Humans
  • Interferon Type I / blood
  • Interferon Type I / therapeutic use
  • Interferon-gamma / pharmacokinetics
  • Interferon-gamma / therapeutic use*
  • Macaca mulatta
  • Recombinant Proteins
  • Rift Valley Fever / prevention & control*


  • Interferon Type I
  • Recombinant Proteins
  • Interferon-gamma